These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 32487089)
1. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089 [TBL] [Abstract][Full Text] [Related]
2. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337 [TBL] [Abstract][Full Text] [Related]
3. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295 [TBL] [Abstract][Full Text] [Related]
4. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. Ni JY; Fang ZT; An C; Sun HL; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH Int J Hyperthermia; 2019; 36(1):841-853. PubMed ID: 31452408 [No Abstract] [Full Text] [Related]
5. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization. Liu Y; Cheng C; Zhou H; Hu S; Wang H; Xie Q; Lei L; Wang P; Liu G; Hu H Bull Cancer; 2021 Oct; 108(10):931-939. PubMed ID: 34247763 [TBL] [Abstract][Full Text] [Related]
6. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma. Carling U; Røsok B; Line PD; Dorenberg EJ Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701 [TBL] [Abstract][Full Text] [Related]
7. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization. Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739 [TBL] [Abstract][Full Text] [Related]
8. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study. Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874 [TBL] [Abstract][Full Text] [Related]
9. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K; Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999 [TBL] [Abstract][Full Text] [Related]
10. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016 [TBL] [Abstract][Full Text] [Related]
11. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors. Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303 [TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients. Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803 [TBL] [Abstract][Full Text] [Related]
13. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811 [TBL] [Abstract][Full Text] [Related]
14. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma. Hansmann J; Evers MJ; Bui JT; Lokken RP; Lipnik AJ; Gaba RC; Ray CE J Vasc Interv Radiol; 2017 Sep; 28(9):1224-1231.e2. PubMed ID: 28688815 [TBL] [Abstract][Full Text] [Related]
15. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Kim JH; Sinn DH; Lee JH; Hyun D; Cho SK; Shin SW; Chang Y; Kim YJ; Yoon JH; Kang W; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Choi MS Dig Dis Sci; 2018 Apr; 63(4):1062-1071. PubMed ID: 29442276 [TBL] [Abstract][Full Text] [Related]
16. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724 [TBL] [Abstract][Full Text] [Related]
17. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases. Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105 [TBL] [Abstract][Full Text] [Related]
18. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686 [TBL] [Abstract][Full Text] [Related]
19. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching. Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976 [TBL] [Abstract][Full Text] [Related]
20. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]